These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36688247)

  • 1. Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
    Cunningham KN; Alsukait S; Cohen SR; Learned C; Gao DX; Kachuk C; Dumont N; Zipeto A; Rosmarin D
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e765-e767. PubMed ID: 36688247
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 3. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
    [No Abstract]   [Full Text] [Related]  

  • 4. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 7. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.
    Kang DH; Kwon SH; Lew BL
    J Dermatol; 2024 Mar; 51(3):e63-e65. PubMed ID: 37950501
    [No Abstract]   [Full Text] [Related]  

  • 8. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
    Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
    [No Abstract]   [Full Text] [Related]  

  • 11. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.
    Tong Z; Zhang Y; Zhou K; Zou Y; Wu Z; Chen J; Zhuang Z; Zhao Y; Gong T; Ji C
    J Am Acad Dermatol; 2023 Oct; 89(4):826-828. PubMed ID: 37307992
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab alleviates pruritus regardless of skin improvement in adults with atopic dermatitis: A cohort study.
    Chen YW; Chen HH; Huang WN; Hsu CY; Chen YH; Hung WT; Tang KT
    J Am Acad Dermatol; 2024 Jan; 90(1):195-196. PubMed ID: 37751779
    [No Abstract]   [Full Text] [Related]  

  • 13. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 14. Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.
    Song X; Liu B; Luan T; Liao S; Tan Y; Peng C; Zhao Z
    Allergy; 2023 Jun; 78(6):1696-1699. PubMed ID: 36708064
    [No Abstract]   [Full Text] [Related]  

  • 15. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
    Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
    [No Abstract]   [Full Text] [Related]  

  • 16. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa.
    Molinelli E; Sapigni C; Simonetti O; Radi G; Gambini D; Maurizi A; Rizzetto G; D'Agostino GM; Offidani A
    Dermatol Ther; 2022 Aug; 35(8):e15645. PubMed ID: 35716015
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab.
    Mazzoni D; Lobo Y; Levitt D; Wheller L
    Pediatr Dermatol; 2022 Jul; 39(4):606-608. PubMed ID: 35575257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Flohr C; Irvine AD; Cork MJ; Simpson EL; Wollenberg A; Deleuran M; Praestgaard A; Thomas RB; Rossi AB
    Br J Dermatol; 2023 Jul; 189(2):238-240. PubMed ID: 37120724
    [No Abstract]   [Full Text] [Related]  

  • 19. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
    Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
    Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series.
    Slodownik D; Levi A; Lapidoth M; Moshe S
    Dermatology; 2022; 238(6):1073-1075. PubMed ID: 35462358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.